Faron Pharmaceuticals Doses First Patient in BLAZE Phase 1/2 Trial
Faron Pharmaceuticals has dosed the first patient in the BLAZE trial, testing bexmarilimab combined with nivolumab for patients with anti-PD-1-resistant NSCLC and melanoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.